With record sales growth of 11 per cent in the first half of this year, Stada’s performance is well above the industry average.
The Stada Group, within which Hemofarm operates, continues to grow significantly, achieving strong results in the first half of 2019. Reported consolidated sales increased 11 per cent in the first half of 2019 to 1.26 billion Euros (2018: Euro 1.14 billion).
On this occasion, Peter Goldschmidt, CEO of Stada, said: “We are particularly pleased that Stada is experiencing strong growth in both our core segments – branded products / OTC and generics, including pharmaceutical specialities.”
Stada saw strong sales growth and significant market share gains in key European markets, including Germany, the United Kingdom, Italy, Spain and France. The company also recorded good growth in the areas of northern and eastern Europe as well as in Asia / the Middle East. In the first half of this year, Stada continued to invest in production capacity and supply chain. As part of the overall optimization of the production network, the company recently opened a new factory in Vietnam with a capacity of four billion tablets. This production site meets the latest GMP EU quality standards so that Stada can supply the European market from Vietnam in the future.
